X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Wockhardt - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs WOCKHARDT LTD. - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. WOCKHARDT LTD. FRESENIUS KABI ONCO./
WOCKHARDT LTD.
 
P/E (TTM) x 22.1 -15.9 - View Chart
P/BV x 3.1 2.6 119.6% View Chart
Dividend Yield % 0.0 1.3 -  

Financials

 FRESENIUS KABI ONCO.   WOCKHARDT LTD.
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
WOCKHARDT LTD.
Mar-17
FRESENIUS KABI ONCO./
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs1761,129 15.6%   
Low Rs79627 12.5%   
Sales per share (Unadj.) Rs37.7363.1 10.4%  
Earnings per share (Unadj.) Rs5.1-20.4 -24.9%  
Cash flow per share (Unadj.) Rs6.7-7.0 -96.4%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs42.5301.8 14.1%  
Shares outstanding (eoy) m158.23110.55 143.1%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x3.42.4 139.7%   
Avg P/E ratio x25.0-42.9 -58.2%  
P/CF ratio (eoy) x18.9-125.9 -15.0%  
Price / Book Value ratio x3.02.9 102.8%  
Dividend payout %0-48.9 0.0%   
Avg Mkt Cap Rs m20,13597,063 20.7%   
No. of employees `0001.26.8 17.0%   
Total wages/salary Rs m7039,665 7.3%   
Avg. sales/employee Rs Th5,176.25,931.8 87.3%   
Avg. wages/employee Rs Th610.41,428.1 42.7%   
Avg. net profit/employee Rs Th699.6-334.0 -209.5%   
INCOME DATA
Net Sales Rs m5,96340,146 14.9%  
Other income Rs m181,143 1.6%   
Total revenues Rs m5,98141,289 14.5%   
Gross profit Rs m1,430128 1,117.3%  
Depreciation Rs m2581,489 17.3%   
Interest Rs m-262,253 -1.2%   
Profit before tax Rs m1,216-2,472 -49.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342-211 -162.1%   
Profit after tax Rs m806-2,260 -35.7%  
Gross profit margin %24.00.3 7,522.0%  
Effective tax rate %28.18.5 329.4%   
Net profit margin %13.5-5.6 -240.0%  
BALANCE SHEET DATA
Current assets Rs m5,10246,160 11.1%   
Current liabilities Rs m2,38519,258 12.4%   
Net working cap to sales %45.667.0 68.0%  
Current ratio x2.12.4 89.2%  
Inventory Days Days150101 148.9%  
Debtors Days Days11394 120.5%  
Net fixed assets Rs m5,14840,165 12.8%   
Share capital Rs m158553 28.6%   
"Free" reserves Rs m6,55632,814 20.0%   
Net worth Rs m6,73233,367 20.2%   
Long term debt Rs m95231,903 3.0%   
Total assets Rs m10,38889,687 11.6%  
Interest coverage x-45.8-0.1 47,130.6%   
Debt to equity ratio x0.11.0 14.8%  
Sales to assets ratio x0.60.4 128.2%   
Return on assets %7.50 -87,447.1%  
Return on equity %12.0-6.8 -176.7%  
Return on capital %14.6-0.3 -4,356.2%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,2989,121 58.1%   
Fx outflow Rs m1,7722,133 83.1%   
Net fx Rs m3,5256,988 50.5%   
CASH FLOW
From Operations Rs m1,274-2,695 -47.3%  
From Investments Rs m-1,204-6,863 17.5%  
From Financial Activity Rs m-19612,545 -1.6%  
Net Cashflow Rs m-1263,010 -4.2%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 2.3 13.0%  
FIIs % 9.6 7.7 124.7%  
ADR/GDR % 0.0 0.1 -  
Free float % 9.1 15.4 59.1%  
Shareholders   42,599 67,757 62.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   NATCO PHARMA  PLETHICO PHARMA  FDC LTD.  TORRENT PHARMA  STRIDES SHASUN LTD  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS